INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

de Verneuil Vanina sold VIR

EVP, General Counsel, Corp Sec · Vir Biotechnology, Inc. · Common Stock

Side
SELL
Value
$27K
Shares
2,407
Price
$11.1
Executed
Nov 3, 2026
Disclosed
Nov 4, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Nov 3 executedNov 4, 2026 disclosed

VIR · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
1/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+1 / 25

    $27K reported value · 2.1% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · VIR

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    5
    DV
    de Verneuil VaninaEVP, General Counsel, Corp Sec
    VIRVir Biotechnology, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$15K
    1,343 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    TL
    Topalian Suzanne LouiseDirector
    VIRVir Biotechnology, Inc.
    Grant or award
    		A—
    8,000 sh
    		Oct 27, 2026Oct 28, 2026
    traded Oct 27, 2026
    		+1dSEC FORM 4

    Evidence

    21
    TL
    Topalian Suzanne LouiseDirector
    VIRVir Biotechnology, Inc.
    Grant or award
    		A—
    4,731 sh
    		Oct 27, 2026Oct 28, 2026
    traded Oct 27, 2026
    		+1dSEC FORM 4

    Evidence

    9
    TL
    Topalian Suzanne LouiseDirector
    VIRVir Biotechnology, Inc.
    Grant or award
    		A—
    16.0K sh
    		Oct 27, 2026Oct 28, 2026
    traded Oct 27, 2026
    		+1dSEC FORM 4

    Evidence

    21
    TL
    Topalian Suzanne LouiseDirector
    VIRVir Biotechnology, Inc.
    Grant or award
    		A—
    9,462 sh
    		Oct 27, 2026Oct 28, 2026
    traded Oct 27, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001628280-26-070025
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 3, 2026
    Published
    Nov 4, 2026
    Ingested by INSIDER
    Nov 4, 22:39 UTC
    Last re-read
    Nov 5, 18:10 UTC

    Extracted facts

    Filer
    de Verneuil Vanina
    Role
    EVP, General Counsel, Corp Sec
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Vir Biotechnology, Inc.
    Ticker
    VIR
    Shares
    2,407
    Price per share
    $11.1
    Value
    $26,718
    Execution date (reported)
    Nov 3, 2026
    Owned after transaction
    110.2K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 2,407
    • Price: $11.1

    = $26,718

    What this establishes

    de Verneuil Vanina filed this Form 4 reporting a open-market sale of VIR on Nov 3, 2026. It became public on Nov 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    EVP, General Counsel, Corp Sec
    de Verneuil Vaninacik:0002036234
    Issuer
    Vir Biotechnology, Inc.cik:0001706431

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.